Scottsdale, Arizona 4/16/2009 1:56:04 AM
News / Finance

Vyteris, Inc. (VYTR.OB) Signs Agreement with Zealand Pharma on Active Transdermal Patch for Peptide Drugs

QualityStocks would like to highlight Vyteris, Inc. (OTCBB: VYTR). The company is the maker of the first active, ready-to-use drug delivery patch (LidoSite®) to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris' proprietary active transdermal smart patch technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration.

 

In the company’s news yesterday,

 

Vyteris, Inc. announced that it has entered into an agreement with Zealand Pharma A/S, a Denmark-based biopharmaceutical company focused on discovering and developing innovative peptide-based drugs, to apply its technology to the controlled transdermal delivery of Zealand Pharma’s peptide optimization technology.

 

“This strategic partnership with Zealand Pharma, a recognized leader in peptide drug development, marks another milestone in the active roll-out of our patented smart patch transdermal technology for the delivery of high-value, therapeutic peptides,” commented Dr. Haro Hartounian, president and chief executive officer of Vyteris, Inc.

 

“Needle-free, tightly controlled delivery of peptides via active, transdermal patches is an innovative and patient-friendly route of administration which can lead to increased safety and compliance. Our ongoing female infertility project with Ferring Pharmaceuticals, Inc. has now entered clinical phase II, and we hope to continue this success in transdermal peptide delivery with our new partner Zealand Pharma,” added Hartounian.

 

First, the two companies will test the feasibility of smart patch-based transdermal delivery of a peptide drug candidate in animal models. Once this study is completed, the companies will decide if they want to further develop and commercialize this peptide or other peptide therapeutics in Zealand Pharma’s product portfolio.

 

“In working with Vyteris and its transdermal delivery technology, we believe this represents a strong collaborative effort to develop innovative new methods of peptide drug delivery that may have significant advantages in efficacy, patient compliance and tolerability,” stated David Solomon, chief executive officer of Zealand Pharma. “With our peptide-based drugs aimed at treating unmet medical needs, we are eager to conduct this feasibility study and apply our knowledge of peptide optimization to Vyteris’ transdermal delivery technology.”

 

About QualityStocks

 

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

 

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.